Related Experiment Videos
R-flurbiprofen: isomeric ballast or active entity of the racemic compound?
G Geisslinger1, S Menzel-Soglowek, W S Beck
1Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Germany.
Agents and Actions. Supplements
|January 1, 1993
Summary
Flurbiprofen enantiomers show distinct effects: S-flurbiprofen reduces inflammation, while R-flurbiprofen causes less gastrointestinal damage. This enantioselective behavior allows for targeted pain and rheumatic disorder treatment.
Area of Science:
- Pharmacology
- Drug Metabolism and Pharmacokinetics
- Inflammation and Pain Research
Background:
- Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation.
- NSAIDs exert their effects primarily through the inhibition of prostaglandin synthesis.
- Understanding the enantioselective properties of drugs is crucial for optimizing therapeutic outcomes and minimizing side effects.
Purpose of the Study:
- To investigate the enantioselective pharmacokinetic and pharmacodynamic behavior of R- and S-flurbiprofen.
- To evaluate the anti-inflammatory and antinociceptive effects of individual flurbiprofen enantiomers.
- To assess the potential for targeted therapeutic applications of pure flurbiprofen enantiomers.
Main Methods:
- Administration of optically pure R- or S-flurbiprofen to various species, including rats and humans.
- Analysis of flurbiprofen enantiomer inversion in vivo.
- Pharmacodynamic studies in rats, including carrageenan-induced paw edema and the Randall-Selitto assay for antinociception.
- Assessment of gastrointestinal mucosal damage.
Main Results:
- Negligible inversion (<5%) of flurbiprofen enantiomers was observed in rats and humans.
- S-flurbiprofen demonstrated significant anti-inflammatory effects, while R-flurbiprofen showed only marginal effects.
- R-flurbiprofen caused significantly less gastrointestinal mucosal damage compared to S-flurbiprofen.
- Both enantiomers exhibited similar potency as antinociceptive agents in rat models of pain.
Conclusions:
- Flurbiprofen enantiomers exhibit distinct pharmacokinetic and pharmacodynamic profiles.
- The S-enantiomer is primarily responsible for the anti-inflammatory activity, whereas the R-enantiomer is associated with reduced gastrointestinal toxicity.
- Enantioselective administration of flurbiprofen offers potential for tailored treatments: R-flurbiprofen for occasional pain and S-flurbiprofen for rheumatic disorders.